Relative Bioavailability of a Single Oral Dose of BI 1358894 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, Fixed Sequence Study)
Latest Information Update: 23 Feb 2025
At a glance
- Drugs BI 1358894 (Primary) ; Itraconazole
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 15 Sep 2020 Results evaluating the effect of a strong CYP3A4 inhibitor (itraconazole [ITZ]) on the pharmacokinetics (PK) of BI 1358894 and its metabolite presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
- 04 Jun 2019 Status changed from recruiting to completed.
- 28 Mar 2019 Status changed from not yet recruiting to recruiting.